Prostate cancer radiotherapy

  • Consultant-led care from experienced prostate cancer oncologists in London, Birmingham and Manchester
  • The full range of prostate cancer radiotherapy, including SABR, MR-Linac and brachytherapy
  • Personalised treatment plans and follow-up care, supported by a dedicated multidisciplinary team
man on the phone

Private prostate cancer radiotherapy at HCA UK

Why choose us?

From image-guided MR-Linac technology to the full range of brachytherapy techniques, here's what makes prostate cancer radiotherapy at HCA UK different.

Radiotherapy is one of the main treatment options for prostate cancer and can be used at different stages - as a primary treatment for localised or locally advanced prostate cancer, alongside hormone therapy for higher-risk disease, or to treat cancer that has returned after surgery.

The type of radiotherapy recommended for you will depend on the stage and grade of your cancer, your overall health and your personal preferences. Your oncologist will explain why radiotherapy has been recommended, what it involves and any possible side effects, so that you can make an informed decision about your treatment and care.

If radiotherapy forms part of your treatment plan, you’ll be cared for by some of the UK’s leading cancer specialists. At HCA UK we offer the full range of prostate cancer radiotherapy, including the latest image-guided technology, to deliver precise, effective treatment shaped around your individual diagnosis.

You'll have a named consultant oncologist who personally leads your radiotherapy - from planning scans and first consultations through to your treatment sessions and follow-up appointments.

They will work closely with your wider clinical team to ensure your radiotherapy is carefully planned alongside your other treatment.

At HCA Healthcare UK we provide the latest treatments and advanced technology. From MR-linac, to SABR and Brachytherapy, we are delivering highly targeted, personalised radiotherapy, often in fewer treatment sessions and with less side effects.
At HCA UK, your radiotherapy is planned and delivered by our  team of specialists - including clinical oncologists, radiographers, medical physicists and dosimetrists - all working together to deliver exceptional care.

This means your plan is coordinated from the start, with every member of your team involved in designing a treatment that is as personalised, precise and effective as possible.
mr linac imaging

Types of prostate cancer radiotherapy at HCA UK

The type of radiotherapy recommended for you will depend on the stage and grade of your cancer, your overall health and your personal preferences. Your consultant will explain each option clearly and help you understand what each involves, so you can make an informed decision together.

Find out more about the different types of radiotherapy that may be recommended as part of your personalised treatment plan.

External beam radiotherapy delivers radiation to the prostate from outside the body. Modern external beam techniques for prostate cancer are highly precise, shaped around the prostate to minimise exposure to the bladder and rectum.

Image-guided radiotherapy (IGRT) uses imaging - such as daily X-rays or ultrasound - at the point of treatment to check the position of the prostate before each session. This helps to account for any movement of the prostate between appointments and ensures the radiation is delivered to exactly the right place.

Intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) are the most widely used external beam techniques for prostate cancer. They use computers to shape radiation beams precisely around the prostate, varying the dose intensity to minimise exposure to the surrounding bladder, rectum and other healthy tissue.

VMAT - sometimes called RapidArc - delivers treatment in continuous arcs around the body and can often be given in shorter sessions than standard IMRT. Both techniques are given in daily sessions over several weeks.

The Elekta Unity MR-Linac combines MRI scanning with radiotherapy delivery, allowing our oncology teams to see the prostate clearly in real time during each treatment session. This is particularly valuable for prostate cancer, because the prostate can shift position as the bladder and bowel fill and empty.

With MR-Linac, the team can see these changes and adapt the treatment plan each day and in real time - ensuring the radiation is targeted precisely to the prostate, while further protecting the bladder, rectum and surrounding structures.

Your consultant will discuss whether MR-Linac is suitable for your diagnosis as part of your personalised treatment plan.

SABR - also known as stereotactic body radiotherapy (SBRT) - delivers a higher dose of radiation at each session, precisely targeted to the prostate. Because each dose is larger and more concentrated, the full course of treatment can usually be completed in just four to five sessions.

SABR is a highly effective treatment option for localised prostate cancer with the significant benefit of a much shorter treatment course. Your oncologist will discuss whether SABR is a suitable treatment for you. 

At HCA UK, SABR for prostate cancer can be delivered using advanced linac technology, including MR-Linac where appropriate, for the highest level of precision.

Brachytherapy is a form of internal radiotherapy that places a radioactive source directly inside or very close to the prostate gland. It delivers a high, targeted dose of radiation to the cancer while limiting exposure to the surrounding tissue. Brachytherapy may be used on its own or in combination with external beam radiotherapy, depending on your individual diagnosis.

Permanent seed brachytherapy - also called low dose rate (LDR) brachytherapy - involves implanting small radioactive seeds, about the size of a grain of rice, directly into the prostate gland. The seeds are permanently placed during a single procedure under general or spinal anaesthetic, and slowly release a low dose of radiation over several months, destroying the cancer cells.

Once the radiation has been fully delivered, the seeds remain in place but are no longer active. This is a well-established treatment for low to intermediate-risk localised prostate cancer. It is usually performed as a day case, and most men are able to return to normal activities within a few days.

Your consultant will discuss whether permanent seed brachytherapy is suitable for your diagnosis and what to expect during and after the procedure.

 

High dose rate (HDR) brachytherapy uses a temporary radioactive source, placed inside the prostate via thin tubes (catheters) under general anaesthetic, to deliver a precisely targeted, high dose of radiation. The source is withdrawn after treatment - no radioactive material is left inside the body.

HDR brachytherapy is usually given as one or two sessions and is most commonly used alongside external beam radiotherapy for intermediate or high-risk prostate cancer, to boost the dose delivered to the prostate.

Your consultant will discuss whether HDR brachytherapy is appropriate for your diagnosis, and how it would fit into your overall treatment plan.

For men with higher-risk or locally advanced prostate cancer, hormone therapy is often recommended alongside radiotherapy. Lowering testosterone levels makes prostate cancer cells more sensitive to radiation, improving the effectiveness of treatment. In advanced prostate cancer the additional hormone therapy with Androgen Receptor Targeted Agents (ARTAs) is often recommended. 

Hormone therapy is usually started before radiotherapy begins and continued during and after the radiotherapy course. The length of hormone therapy recommended will depend on the risk level of your cancer - it may be recommended for a few months to several years.

Your oncologist and urologist will discuss whether hormone therapy is recommended alongside your radiotherapy, and what this involves. The combination of hormone therapy and radiotherapy is well established and has been shown to significantly improve outcomes for men with higher-risk prostate cancer.
male patient having a scan

Your prostate cancer team

Our oncologists are highly experienced in delivering the full range of prostate cancer radiotherapy, including advanced image-guided and brachytherapy techniques. They will explain your treatment options, make a recommendation based on your individual diagnosis and answer any questions you have, so that you can make an informed decision about your treatment and care.

Working closely with your chosen consultant, you will receive the dedicated support of a named Clinical Nurse Specialist (CNS) who specialises in prostate cancer and its treatment. They will provide expert support throughout your treatment and follow-up care. They can also refer you to other specialists who are here to support you, such as psychologists, physiotherapists and other support services, when needed.

Your treatment plan is designed and delivered by our team of specialists - including clinical oncologists, radiographers, medical physicists and dosimetrists - all working together. This integrated approach means your care is coordinated from the start, with any adjustments made efficiently throughout your treatment.

Prostate cancer radiotherapy FAQs

Most men experience some side effects from radiotherapy, but advanced technology and treatment techniques mean that prostate cancer radiotherapy is delivered with fewer side effects than ever before. 

The effects you experience will depend on the type of radiotherapy and the area being treated. Your consultant will talk you through the specific side effects associated with your recommended treatment before you start.

Common side effects of prostate cancer radiotherapy include:

  • Urinary changes - you may need to urinate more frequently or more urgently during treatment. Most urinary side effects improve after treatment ends, though some men notice longer-term changes
  • Bowel changes - loose stools, urgency or discomfort are common, particularly with external beam radiotherapy. These usually settle within weeks of finishing treatment
  • Fatigue - one of the most common effects of radiotherapy, which can build up during treatment and continue for some weeks afterwards. Your team can advise on managing this
  • Erectile dysfunction - radiotherapy can affect the nerves and blood vessels responsible for erections. This may develop gradually over months or years after treatment. Your team can discuss options to help with this
  • Skin changes redness or soreness in the treated area, which usually settles after treatment ends

If you have any concerns about side effects during or after your treatment, speak to your Clinical Nurse Specialist. During your treatment, you'll also have access to the LOC triage line which is available 24 hours a day, staffed by experienced cancer nurses*

*Triage is provided by the Christie Hotline for patients receiving treatment in Manchester.

The side effects of brachytherapy are similar to external beam radiotherapy, though urinary side effects can be more prominent in the first 6 months. Patients must have a good urine flow to make brachytherapy a good option, and this is tested with a urine flow test to see if you are suitable. There is good long-term data of over 20 years outcomes with brachytherapy for prostate cancer and it has reduced risks of bowel side effects and lower risks of erectile dysfunction that radiotherapy. Your consultant will explain what to expect based on your specific treatment.

Radiotherapy uses high-energy X-rays to destroy cancer cells in the prostate gland. It can be given externally - using a machine outside the body - or internally, by placing a radioactive source directly into the prostate (brachytherapy).

For prostate cancer, radiotherapy is most commonly used as a primary treatment for localised or locally advanced disease, or alongside hormone therapy for higher-risk cancers. It may also be used after surgery if the cancer returns, or to treat cancer that has spread to the bones.

Radiotherapy may be recommended based on the stage and grade of your prostate cancer, your overall health and personal preferences, and whether surgery or other treatments are also an option for you. For many men with localised prostate cancer, radiotherapy and surgery offer comparable outcomes - your consultant will help you understand both options.

Your consultant and Clinical Nurse Specialist will explain clearly why radiotherapy has been recommended, what it involves and any possible side effects, so that you can make an informed decision about your treatment and care.

External beam radiotherapy delivers radiation to the prostate from outside the body, using a machine (linear accelerator) that directs beams of radiation at the prostate from several angles. Modern external beam techniques are highly precise, shaped around the prostate to protect the bladder and rectum.

Brachytherapy delivers radiation from inside the body, by placing radioactive seeds (permanently) or a temporary radioactive source directly into the prostate. Brachytherapy delivers a concentrated, high dose of radiation to the prostate while sparing nearby structures. Both approaches are effective and your consultant will discuss which is most appropriate for your diagnosis.

SABR - stereotactic ablative radiotherapy - is an advanced external beam technique that delivers a precisely targeted, high dose of radiation to the prostate in just four to five sessions, rather than the 20 or more sessions needed with conventional radiotherapy.

SABR uses very precise imaging and targeting technology to ensure the radiation reaches the prostate accurately each time. For suitable men, it provides comparable effectiveness to conventional radiotherapy, with the significant benefit of a much shorter treatment course. Your consultant will discuss whether SABR is appropriate for your diagnosis.

MR-Linac combines an MRI scanner with a radiotherapy machine, allowing our oncology teams to see the prostate clearly in real time during each treatment session. This is particularly valuable for prostate cancer because the prostate can shift slightly in position as the bladder and bowel fill and empty.

With MR-Linac, the treatment plan can be adapted each day to account for these changes - ensuring radiation is delivered precisely to the right place, while protecting the bladder, rectum and surrounding tissue. Your consultant will discuss whether MR-Linac radiotherapy is suitable for your diagnosis.

Radiotherapy may be recommended after surgery if cancer cells are found at the edge of the removed tissue (positive margins), or if your PSA level begins to rise after surgery - a sign that some cancer may remain or have returned.

Radiotherapy given after surgery to reduce the risk of the cancer returning is called adjuvant radiotherapy. If given later, when there is evidence of recurrence, it is known as salvage radiotherapy. Your consultant will discuss whether post-surgical radiotherapy is appropriate for you and what it involves.

The most common side effects of prostate cancer radiotherapy affect the urinary system and bowel - including more frequent urination, urgency and loose stools during and after treatment. These usually improve after treatment ends, though some men notice longer-term changes. Erectile dysfunction can develop gradually over time after radiotherapy.

Not everyone experiences all side effects, and your oncology team will discuss what to expect from your specific treatment. Your Clinical Nurse Specialist will be available throughout to support you, and you'll have access to the LOC 24/7 triage line during your treatment.

The length of your radiotherapy course depends on the type and technique recommended. Conventional external beam radiotherapy is usually given over 4 to 7 weeks (Monday to Friday). Hypofractionated schedules deliver the same total dose in a shorter course - often 4 to 5 weeks. SABR condenses the full course into just four to five sessions.

Brachytherapy is typically completed in a single procedure (permanent seeds) or one to two sessions (HDR). Your oncologist will explain the expected duration of your specific treatment plan.